Sector News

GlobeImmune axes ‘majority’ of staffers in wake of trial failure

June 10, 2015
Life sciences
Two weeks after GlobeImmune conceded that its Gilead-partnered hepatitis B vaccine had flunked out of a key Phase II study, the Louisville, CO-based biotech said it laid off “the majority” of its staff.
 
“Following our recent data announcement in our hepatitis B program, this workforce reduction is a necessary action to conserve working capital and provide maximum flexibility in determining the future direction of GlobeImmune,” said GlobeImmune CEO Timothy Rodell in a statement.
 
Recruiting 178 patients with chronic hep B, GlobeImmune tested GS-4774 in combination with standard oral antivirals, finding that the vaccine charted no improvement in hep B surface antigen levels, a key measure of viral activity, compared to the older drugs alone. At 24 weeks, even the highest doses of GS-4774 failed to meet the study’s primary endpoint, GlobeImmune said, though the vaccine did chart a positive–but not statistically significant–effect after 48 weeks.
 
Pointing to three patients who got the highest dose and posted notable surface antigen reductions, GlobeImmune said at the time that it believed the trial “suggests initial biologic activity” for GS-4774. The vaccine was also safe and well tolerated in the study, the company said.
 
Investors were less optimistic, sending the company’s shares into a meltdown that wiped out half of its market cap.
 
By John Carroll
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”